Blood-derived therapies show promise in treatment of ocular surface diseases

Ongoing research increasingly shows that autologous serum and plasma-derived therapies are generally useful in the treatment of ocular surface disorders such as dry eye syndrome and persistent epithelial defect, according to a report.However, the potential high cost and inconvenience of processing blood products restrict more widespread use of these agents, the authors said.